May 2011

India has, so far, failed to get any assurance from the European Union to reconsider its ban on Indian herbal medicines even though the issue was raised at the EU through the official channel several times.

The ban has come into effect from May 1, 2011, following a new EU regulatory procedure that was approved seven years back.

ABOUT GANPAT UNIVERSITY

PharmaShine - 2011, which is organised by PharmaTutor and OPUBS, met success and called end of the event by announcing Top most articles.

As we announce that Top 3 articles are awarded publication in CYS-International Journal. But we decided that not only three but other also who are near by the winners, will also publish in CYS as merit award after peer review.

About Author: Mr.Mahendra G. Pawar* (B.Pharmacy) Ms.Komal  R. Nikam (B.Pharmacy), Mr.Rakesh D.Amrutkar (M.Pharmacy)

Reference ID: PHARMATUTOR-ART-1059

Abstract
Biotechnologists in recent years have come up with a new concept.This new concept is about edible vaccine. The difference here lies, that crops like “golden rice” provided extra nutrition that naturally didn’t occur in it. But edible vaccines are GM crops that would provide extra added “immunity” from certain diseases.
Edible vaccines are composed of antigenic proteins and do not contain pathogenic genes (because obviously they use attenuated strains). Thus, they have no way of establishing infection and safety is assured.Oral administration is possible , production is highly efficient and can be easily scaled up.For example, hepatitis-B antigen required to vaccinate whole of China annually, could be grown on a 40-acre plot and all babies in the world each year on just 200 acres of land,Cheaper (single dose of hepatitis-B vaccine would cost approximately 23 paise), grown locally using standard methods and do not require immense capital investment of pharmaceutical manufacturing facilities, exhibit good genetic stability. Do not require special storage condition. Since syringes and needles are not used chances of infection are also less. Fear of contamination with animal viruses - like the mad cow disease, which is a threat in vaccines manufactured from cultured mammalian cells - is eliminated, because plant viruses do not infect humans.

About Author: A. A. Durgavale*, M. V. Mahale, S. R. Kane, Dr. S. K. Mohite, Dr. C. S. Magdum
Department of Quality Assurance,
Rajarambapu College Of  Pharmacy,
Kasegaon, Tal - Walwa, Dist. - Sangli - 415404

Reference ID: PHARMATUTOR-ART-1058

Abstract
Intellectual Property (IP) refers to property created with the use of intellect. In other words, this refers to creation of mind. These are rights given to person over creation of their minds. They usually give the creator an exclusive right over use of his or her relation for certain period of time. Intellectual property differs from other form of properties as it does not have any physical shape and can be seen. Protection of Intellectual property is done by offering time limited rights to investor in form of patents.
Intellectual property laws vary from jurisdiction to jurisdiction, such that the acquisition, registration or enforcement of IP rights must be pursued or obtained separately in each territory of interest. However, these laws are becoming increasingly harmonized through the effects of international treaties such as the 1994 World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs), while other treaties may facilitate registration in more than one jurisdiction at a time. Certain forms of IP rights do not require registration in order to be enforced. There are various forms of IP like Copyrights and related rights, Trade Marks, Geographical Indications, Industrial Designs, Lay out Designs of Integrated Circuits, Protection of Undisclosed Information (Trade Secrets), Patents, Plant varieties.

About Author: Dr.Ravindra Kembhavi, Asso. Professor PSM Department,
KEM hospital, Parel, Mumbai
Dr.Mahesh Ghadage, M.Sc pharmaceutical 2^nd year student,
KEM hospital, Parel, Mumbai

Reference ID: PHARMATUTOR-ART-1057

Abstract
Severe or complicated P. vivax malaria seldom results in pulmonary damage, and pulmonary complications are exceedingly rare while acute renal failure, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), hypoglycemia, coma, or epileptic seizures this are manifestations of severe or complicated  P. falciparum malaria.

About Author: Khuntia  Bhabani  S.,  M.Pharm.,  B.P.U.T.,
Department  of  Pharmaceutical  Analysis  and  Quality  assurance,
Royal  College  of  Pharmacy  and  Health  Sciences,  
Berhampur, Odisha, India

Reference ID: PHARMATUTOR-ART-1056

Abstract
The present study includes a simple, sensitive and specific UV method development and validation for the quantitation of Drotaverine in bulk and pharmaceutical dosage form. The λmax was found to be 357nm by taking acetonitrile and water (50:50) as solvent. The validation of the proposed method was carried out as per ICH Guidelines. It was found that the drug was shown the linearity between the range 5-90µg/ml. The regression of the curve was y = 0.022x - 0.033. The developed method was found to be with %RSD 0.548499 for Drotaverine. The %RSD for intra-day and inter-day precision was lower than 2%. The percentage recovery values of pure drug from the reanalyzed solution of formulation were in between 95.68-99.5%. The ruggedness of the method was studied by taking in account of different analyst and by varying the temperature. Based on the performance characteristic the proposed UV method was found to suitable for the estimation of Drotaverine in bulk and pharmaceutical dosage form.